Nephron Research downgraded Tandem Diabetes (TNDM) to Hold from Buy with a $14 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $13 from $20 at Wells Fargo
- Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler
- Tandem Diabetes Care Reports Record Q2 2025 Sales
- Tandem Diabetes Care: Strong Revenue Performance and Promising Portfolio Justify Buy Rating Despite Challenges
- Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings